(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck said Friday it’s has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion. The drug company MRK will pay an upfront $700 million in cash to ...

Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases. Merck will acquire full global rights to clinical-stage bispecific antibody ...

Merck MRK announced that it has entered into a definitive agreement with Cayman Islands-based privately-held biotech company Curon Biopharmaceutical to acquire the latter’s next-generation ...

Per the terms of the deal, Merck will acquire the global rights (excluding Greater China) to develop and market HRS-5346. In return, Hengrui Pharma will receive an upfront cash payment of $200 ...

By Sriparna Roy (Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck's stock was down 0.2% but has gained 4.5% in the year to date, while the SPDR S&P Biotech exchange-traded fund XBI has gained 6% and the S&P 500 SPX has gained 11.7%. -Ciara Linnane ...